Nordic Nanovector ASA (NANO):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Nordic Nanovector ASA (NANO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8240)・商品コード:DATA904C8240
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:47
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of haematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for the treatment of non-Hodgkin Lymphoma, a life-threatening blood cancer. Its Betalutin consists of tumour-specific antibody HH1, which targets CD37 antigen on the surface of NHL cells. Nordic Nanovector develops products for the treatment of multiple cancer indications by utilizing innovative therapy programmes and patented technologies. The company evaluates chimeric anti-CD37 antibodies with different payloads for the treatment of both types of leukaemia. It operates in Norway, Switzerland and the UK. Nordic Nanovector is headquartered in Oslo, Norway.

Nordic Nanovector ASA (NANO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Nordic Nanovector Raises USD8.34 Million In A Financing Round 11
Nordic Nanovector Raises US$10 Million In Series A Financing 12
Nordic Nanovector Raises US$2.4 Million In Venture Financing 13
Partnerships 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Nordic Nanovector Enters into Partnership with LegoChem Biosciences 15
Nordic Nanovector Enters into Agreement with Areva Med 16
Nordic Nanovector Enters into R&D Agreement with Paul Scherrer Institute 17
Nordic Nanovector Enters into Co-Development Agreement with Affibody 18
Equity Offering 19
Nordic Nanovector Raises USD1.2 Million in Rights Offering of Shares 19
Nordic Nanovector Raises USD59 Million in Private Placement of Shares 20
Nordic Nanovector Completes IPO 21
Nordic Nanovector Raises USD7.7 Million in Rights Offering of Shares 23
Nordic Nanovector Raises USD41.7 Million in Private Placement of Shares 24
Nordic Nanovector ASA – Key Competitors 25
Nordic Nanovector ASA – Key Employees 26
Nordic Nanovector ASA – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 22, 2018: Nordic Nanovector: results for the second quarter and first half 2018 28
May 30, 2018: Nordic Nanovector – Results for the First Quarter 2018 31
Feb 27, 2018: Nordic Nanovector- Results for the Fourth Quarter and Full Year 2017: Solid Performance Through 2017, Moving Forward With Pivotal Trial 32
Nov 22, 2017: Nordic Nanovector – Results for the Third Quarter 2017 34
Aug 23, 2017: Nordic Nanovector – Results for Second Quarter and First Half Year 2017 36
May 24, 2017: Nordic Nanovector: Results for First Quarter 2017 38
Feb 28, 2017: Nordic Nanovector: Results for Fourth Quarter and Full Year 2016 39
Corporate Communications 40
Jun 01, 2018: Nordic Nanovector Strengthens Management Team With Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy 40
May 30, 2018: Nordic Nanovector Names Rainer Boehm As Board Director 41
Apr 20, 2018: Nordic Nanovector Appoints Tone Kvale As Interim Chief Executive Officer 42
Apr 04, 2018: Nordic Nanovector announces that Luigi Costa will step down as Chief Executive Officer 43
Product News 44
01/04/2017: Nordic Nanovector to Present at Biotech Showcase 2017 44
Clinical Trials 45
Mar 15, 2018: Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumour Effect of Humalutin in Three Lymphoma Models at AACR 2018 45
Mar 17, 2017: Nordic Nanovector announces first patient dosed in Phase 1 study of Betalutin in diffuse large B-cell lymphoma, an aggressive form of NHL 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Deals By Therapy Area, 2012 to YTD 2018 9
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nordic Nanovector Raises USD8.34 Million In A Financing Round 11
Nordic Nanovector Raises US$10 Million In Series A Financing 12
Nordic Nanovector Raises US$2.4 Million In Venture Financing 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Nordic Nanovector Enters into Partnership with LegoChem Biosciences 15
Nordic Nanovector Enters into Agreement with Areva Med 16
Nordic Nanovector Enters into R&D Agreement with Paul Scherrer Institute 17
Nordic Nanovector Enters into Co-Development Agreement with Affibody 18
Nordic Nanovector Raises USD1.2 Million in Rights Offering of Shares 19
Nordic Nanovector Raises USD59 Million in Private Placement of Shares 20
Nordic Nanovector Completes IPO 21
Nordic Nanovector Raises USD7.7 Million in Rights Offering of Shares 23
Nordic Nanovector Raises USD41.7 Million in Private Placement of Shares 24
Nordic Nanovector ASA, Key Competitors 25
Nordic Nanovector ASA, Key Employees 26
Nordic Nanovector ASA, Subsidiaries 27

List of Figures
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Nordic Nanovector ASA (NANO):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8240)販売に関する免責事項を必ずご確認ください。
★調査レポート[Nordic Nanovector ASA (NANO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆